Examining metastatic lymph nodes in each part of the stomach's mesentery during gastrectomy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study enrolls adults with primary gastric adenocarcinoma (cT2–4aN0–3M0) who undergo gastrectomy with D2 lymphadenectomy plus complete mesogastric excision at The First Affiliated Hospital, Zhejiang University. Investigators will examine the presence of metastatic lymph nodes within each of six predefined gastric mesenteries and record how many mesenteries are involved. They will correlate mesentery involvement and number of metastatic mesenteries with standard TNM staging and patient outcomes to determine prognostic value. Key exclusions include prior neoadjuvant therapy, prior upper abdominal surgery, total or proximal gastrectomy, BMI >30, and other concurrent malignancies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged older than 18 years and younger than 85 years
2. Primary gastric adenocarcinoma confirmed by preoperative pathology result
3. cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition
4. Patients who received gastrectomy with D2 lymphadenectomy plus complete mesogastric excision
5. American Society of Anesthesiologists (ASA) class I, II, or III
6. Written informed consent

Exclusion Criteria:

1. Negative preoperative biopsy
2. Too late tumour stage or metastasis (cT4b/M1)
3. BMI\>30 kg/m2
4. Total gastrectomy or proximal gastrectomy
5. previous neoadjuvant chemotherapy or radiotherapy
6. Previous upper abdominal surgery
7. Combined with other malignant diseases
8. Reject operation

Where it's running

• Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Tao Wang, Ph.d
• Email: 15002740874@163.com
• Phone: +86-197-068-25286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• Microplastic exposure and progression of stomach precancerous changes

  This project will test if adults with higher microplastic exposure are more likely to have precancerous stomach changes or gastric cancer.

  Recruiting Xijing Hospital of Digestive Diseases · Xi'an, Shaanxi · NCT07542652

• Disitamab vedotin plus trastuzumab and tislelizumab versus chemotherapy plus trastuzumab (± pembrolizumab) for HER2‑high advanced gastric or gastroesophageal junction adenocarcinoma

  This trial tests whether combining disitamab vedotin with trastuzumab and the immunotherapy tislelizumab works better than standard chemotherapy with trastuzumab (with or without pembrolizumab) as first‑line treatment for people with HER2‑high advanced gastric or gastroesophageal junction cancer.

  Recruiting Phase 3 RemeGen Co., Ltd. · Beijing, BJ-Beijing · NCT07315750

• Using the PAGODA algorithm to guide FOLFOX dose changes and reduce unplanned chemotherapy delays

  This trial will test whether using the PAGODA algorithm to guide dose changes during FOLFOX chemotherapy for people with gastrointestinal cancers can reduce unplanned treatment delays.

  Recruiting at 391 sites Alliance for Clinical Trials in Oncology · Fairbanks, Alaska and 397 other locations · NCT07283939

• Indocyanine green to highlight tumor depth and margins during endoscopic removal of esophageal or stomach cancer

  This trial will test whether a dye called indocyanine green can help doctors see the depth and edges of superficial esophageal or stomach cancers during endoscopic submucosal dissection.

  Recruiting Phase 1/2 University Medical Center Groningen · Groningen, Provincie Groningen · NCT07108855

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.